Gene Therapy Market (2019–2026) to See Extensive Worldwide Growth
Gene Therapy Market accounted for $584 million in 2016, and is estimated to reach $4,402 million by 2023, registering a CAGR of 33.3% from 2017 to 2023. North America is the highest contributor in the gene therapy market in 2016; however, Asia-Pacific is expected to witness the highest growth rate during the forecast period.
The increase in funding for R&D activities pertaining to gene therapy and increase in awareness regarding gene therapy are the major factors that drive the gene therapy market growth. In addition, increase in government support, ethical acceptance of gene therapy for cancer treatment, and rise in prevalence of cancer can fuel the growth of the gene therapy market. However, high cost associated with the treatment and unwanted immune responses are expected to hamper the growth of the gene therapy market.
Download PDF Report Sample with statistical info @ https://www.alliedmarketresearch.com/request-sample/2841
The report provides a comprehensive analysis of the key players operating in the global gene therapy market industry, namely Adaptimmune Therapeutics Plc., Anchiano Therapeutics Ltd., Achieve Life Sciences, Inc., Adverum Biotechnologies, Inc., Abeona Therapeutics Inc., Applied Genetic Technologies Corporation, Arbutus Biopharma Corporation, Audentes Therapeutics, Inc., AveXis, Inc., Bluebird Bio, Inc., Celgene Corporation, CRISPR Therapeutics AG, Editas Medicine, Inc., Editas Medicine, Inc., GlaxoSmithKline Plc., Intellia Therapeutics, Inc., Merck & Co., Inc., Novartis AG, REGENXBIO Inc., Spark Therapeutics, Inc., Sangamo Therapeutics, Inc., Uniqure N. V., Voyager Therapeutics, Inc.
Other prominent players in the value chain (companies not profiled in the report) includes Amgen, Epeius Biotechnologies, Sanofi, Juno Therapeutics, and Advantagene.
Key Findings of the Gene Therapy Market:
Non-viral vectors segment is projected to grow at the highest rate with the CAGR of 34.6% during the analysis period. Oncological disorders segment generated the highest revenue, and is expected to continue its dominance in future in the global gene therapy market. Asia-Pacific is projected to grow at the fasted CAGR during the forecast period. China is expected to grow highest in the Asia-Pacific region during the forecast period. Tumor suppressor is the expected to grow fastest during the forecast period.
Make an Enquiry for Purchase Report @ https://www.alliedmarketresearch.com/purchase-enquiry/2841
Table of Content:
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits
1.3. Key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. Top player positioning, 2018
3.4. Porter’s five forces analysis
3.5. Market dynamics
188.8.131.52. High investment for R&D activities pertaining to gene therapy
184.108.40.206. Increase in prevalence of cancer
220.127.116.11. Growth in awareness regarding gene therapy
18.104.22.168. High cost associated with gene therapies
22.214.171.124. Unwanted immune responses
126.96.36.199. Untapped potential for emerging markets